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Abstract
Background: In order to detect levels of pre-existing cross-reactive antibodies in different age groups and to measure age-
specific infection rates of the influenza A (H1N1) 2009 pandemic in Germany, we conducted a seroprevalence study based
on samples from an ongoing nationwide representative health survey.
Methodology/Principal Findings: We analysed 845 pre-pandemic samples collected between 25 Nov 2008 and 28 Apr 2009
and 757 post-pandemic samples collected between 12 Jan 2010 and 24 Apr 2010. Reactive antibodies against 2009
pandemic influenza A (H1N1) virus (pH1N1) were detected using a haemagglutination inhibition test (antigen A/California/
7/2009). Proportions of samples with antibodies at titre $40 and geometric mean of the titres (GMT) were calculated and
compared among 6 age groups (18–29, 30–39, 40–49, 50–59, 60–69, $70 years). The highest proportions of cross-reactive
antibodies at titre $40 before the pandemic were observed among 18–29 year olds, 12.5% (95% CI 7.3–19.5%). The highest
increase in seroprevalence between pre- and post-pandemic was also observed among 18–29 year olds, 29.9% (95% CI
16.7–43.2%). Effects of sampling period (pre- and post-pandemic), age, sex, and prior influenza immunization on titre were
investigated with Tobit regression analysis using three birth cohorts (after 1976, between 1957 and 1976, and before 1957).
The GMT increased between the pre- and post-pandemic period by a factor of 10.2 (95% CI 5.0–20.7) in the birth cohort
born after 1976, 6.3 (95% CI 3.3–11.9) in those born between 1957 and 1976 and 2.4 (95% CI 1.3–4.3) in those born before
1957.
Conclusions/Significance: We demonstrate that infection rates differed among age groups and that the measured pre-
pandemic level of cross-reactive antibodies towards pH1N1 did not add information in relation to protection and prediction
of the most affected age groups among adults in the pandemic.
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Introduction
The 2009 pandemic influenza A (H1N1) emerged in April 2009
and spread rapidly to countries worldwide [1–4]. The antigenic
distance from seasonally circulating influenza A (H1N1) viruses
raised discussion about the level of pre-existing immunity and
immunisation strategies [5]. On 29 Apr 2009 the first laboratory
confirmed case in Germany was registered. While initially the
majority of cases were in young adults and travel related, the
pandemic wave at the population level started in autumn in
school-aged children and rapidly spread throughout Germany and
peaked in middle of Nov 2009 [6,7]. The pandemic vaccination
campaign in Germany started on 26 Oct 2009. The total number
of notified cases until the calendar week 17/2010 was 172 499 and
the highest notification rates were reported in the age group of
5–14 years and – as in other countries in Europe – elderly adults
above 60 years were less frequently reported [8].
This observation seemed plausible in the context of previously
circulating H1N1 strains as a potential cause of pre-existing cross-
reactive antibodies against pH1N1 [9]. Part of the population had
been exposed to descendants of the 1918 H1N1 pandemic virus
circulating until 1957, when it was replaced by H2N2, and after
1977, when H1N1 reappeared in humans again [10,11]. Thus, it
was expected that the risk of infection was lower among older
individuals. This hypothesis was supported by results of seroprev-
alence studies demonstrating that cross-reactive antibodies in the
samples collected in the pre-pandemic period were more prevalent
among the elderly [9,12–18]. However, there was evidence
suggesting that the degree of pre-pandemic serological cross-
reactivity varied markedly between populations worldwide [17].
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in different age groups and to measure age specific infection rates
of the influenza A (H1N1) 2009 pandemic in Germany, we
conducted a seroprevalence study based on samples from an
ongoing representative nationwide interview and examination
survey for adults that had started 6 months prior to the first
registered case of influenza A (H1N1) 2009 in Germany.
Materials and Methods
Study population
The German Health Interview and Examination Survey for
Adults (DEGS) [19] is a nationally representative health survey of
the adult population in Germany. The DEGS survey is a part of
the continuous Health Monitoring and was designed to be
representative regarding age, sex and region of residence for the
non-institutionalized adult population in Germany. The total
sample of 7,500 individuals is being collected between Nov 2008
and Nov 2011 as a stratified two-stage cluster sample. Two
professionally trained teams each visit 30 sample points (munic-
ipalities) per year, which add up to 180 sample points for the whole
study. The sample points are distributed over Germany according
to federal state and municipality size in order to reflect the
distribution of the German population. The study participants fill
in questionnaires, pass physical tests, give blood and urine samples,
and have a standardized interview by a physician. In the present
study, participants from 46 sample points were included. The
study was approved by the Ethics Committee of Charite ´,
University Medicine, Berlin, Germany.
Sera collection
The pre-pandemic sera were drawn between 25 Nov 2008 and
28 Apr 2009 and post-pandemic sera were drawn between 12 Jan
2010 and 24 April 2010. The sera represent all DEGS study
participants of these periods from whom serum samples were
available for analysis.
The regions that were covered in this study are distributed
across Germany.
Laboratory procedures
Serum samples were analysed for antibodies to pH1N1 by a
validated microtiter hemagglutination-inhibition (HI) test as
previously described [20], using the reference strain A/Califor-
nia/7/2009 as antigen. Validation of the HI test was performed by
comparative studies. Sera obtained from H1N1 (2009) PCR-
positive patients were analysed in a comparative study by the
National Reference Centre for Influenza (NIC), Germany, and
also by the Paul-Ehrlich-Institute, Langen, Germany. Moreover,
samples collected from persons vaccinated with the pandemic
H1N1 (2009) vaccine were analysed by the National Institute for
Biological Standards and Control (NIBSC), London, UK, the
Paul-Ehrlich-Institute and the NIC Germany. Both, the national
and international validation of the HI test revealed comparable
results [21].
As a first step, each serum was treated with receptor-destroying
enzyme to inactivate non-specific inhibitors resulting in a final
serum dilution of 1:10. Sera were then diluted serially twofold into
microtiter plates. The virus was adjusted to 4 HA units/25 ml. This
concentration was verified by back-titration and 25 ml of the virus
suspension was added to each of the 96 wells. After incubation at
room temperature for 30 min, freshly prepared 0.5% turkey red
blood cells were added. The plates were then mixed by using
agitation followed by a further incubation at room temperature for
30 min. Positive and negative controls were included on each
plate. An international pH1N1 serum standard received from the
NIBSC, London, UK, and sera from vaccinated persons served as
controls (titres 40 and 1280). The determination of the HI titre was
performed by identification of the reciprocal of the last serum
dilution which contained non-agglutinated red blood cells. The
titre of the international standard was indicated as 1:183. Using
this standard, a titre of 160 was obtained in different runs. Thus,
confirming reproducibility of the international standard HI titre in
this study.
All samples were tested twice on different days; there were no
samples that differed by more than one dilution step. The
minimum detection limit was 1:10 and samples with titre less than
10 were considered negative and were assigned a value 5 for
calculations of the geometric mean. For the subsequent analysis,
the geometric mean of the two measurements was used as single
observation for each sample.
Data
For detection of sero-prevalence of reactive antibodies we used
pre- and post-pandemic sera. Information about age, sex, and
residence in Germany was available for all samples. Vaccination
status was assessed using information extracted from the
vaccination cards: for those with no vaccination cards, the status
was self-reported. For those with vaccination cards, information on
vaccine type and date of vaccination was available. For the post-
pandemic analysis, we used only the samples with vaccination
cards. This was done in order to control pandemic vaccine effect
on the level of cross-reactive antibodies by excluding these
individuals from further calculations.
Statistical analysis
In both pre-pandemic and post-pandemic samples, we calcu-
lated proportions together with 95% confidence intervals (95% CI)
of antibodies at titre $10 and $40. Furthermore, a gender and
age group (18–29, 30–39, 40–49, 50–59, 60–69, $70 years)
weighted overall mean of these proportions was calculated by
utilising population numbers from the German 2008 population
(source: German Federal Statistical Office). Similarly, an overall
GMT was calculated by exponentiating a population weighted
mean of the strata specific log(GMT)s. For both the overall
proportion and GMT, CIs were calculated by the percentile
method based on 999 draws from two-stage bootstrap cluster
sampling, where first the sample points (municipalities) were
drawn with replacement, then individuals were drawn with
replacement within each sample point [22]. We tested for
differences in GMT in two groups with Wilcoxon test.
For the subsequent regression analysis, only three birth cohorts
(after 1976, between 1957 and 1976, and before 1957 corre-
sponding to age groups 18–32, 33–52 and $53, respectively) were
used in order to increase the power of the analysis. As the observed
titre values range over several orders of magnitude we log-
transformed the response for variance stabilization. A special
problem of the data is that a standard linear regression model for
log(titre) does not apply, because a large proportion of the
measurements (87.2% in pre-pandemic and 67.4% in post-
pandemic samples) are below the detection limit of 1:10, and
hence are left-censored. Instead, we used a Tobit regression model
[23] for the analysis of log(titre) with a value just below log(10) as
left censoring limit. The effects of sampling period (pre- and post-
pandemic), age, sex, and vaccination on log(titre) could now be
investigated. Model selection was performed using a manual
stepwise forward selection procedure based on p-values from two-
sided likelihood ratio tests. Altogether, a p-value below 0.05 was
considered to be statistically significant. All statistical analyses were
Cross-Reactive Antibodies to 2009 Pandemic H1N1
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and R version 2.12.0 [25].
Results
A total number of 845 serum samples for the pre-pandemic
period and 757 for the post-pandemic period could be included in
analysis. The response was 47% which is above average compared
to other large population surveys. For the 845 pre-pandemic
samples information on vaccination in 318 (37.6%) samples was
based on vaccination cards, in 512 (60.6%) on self reporting, and
15 (1.8%) samples had no information on vaccination. From the
757 post-pandemic samples information on vaccination based on
vaccination cards was available for 351 (46.4%) – only these were
used for further analysis.
Median age in the pre-pandemic sample was 54 years (range
18–86, mean 51.3, SD 617.0) and in the post-pandemic it was 47
years (range 18–85, mean 47.5, SD 616.7). Male to female ratio
in the pre-pandemic sample was 0.91 and in post-pandemic 0.86.
In the pre-pandemic sample 43.5% (368/845) of individuals had
been vaccinated at least once in their lifetime with any seasonal
influenza vaccine. In the post-pandemic sample, 30.5% (107/351)
of individuals had been vaccinated with a seasonal vaccine and
further 4.8% (17/351) had been vaccinated with pandemic
vaccine, therefore were excluded from further analysis.
When comparing our study population to the general
population in Germany, no significant differences regarding sex
were found. However there were significant differences in age
distribution (Table S1). This is why weighting procedures have
been performed in parts of the analysis.
Pre-pandemic samples
In the pre-pandemic sample the measured antibody titres
ranged from 10 to 640. The weighted overall GMT in pre-
pandemic sample was 6.2 (95% CI 5.8–6.7). In the six age groups
the GMT ranged from 5.8 to 7.9 as shown in Figure 1 and
displayed in Table S2. GMT in those aged 18 to 29 years (7.9) in
comparison to those 30 years of age and older (5.9) was
significantly higher (Wilcoxon test, p ,0.001).
The overall proportion of cross-reactive antibodies in the pre-
pandemic sample was estimated to be 4.8% (95% CI 2.8–7.0%) at
titre $40. Those aged 18–29 had the highest proportions of cross-
reactive antibodies at titre $10 and $40 (calculations for titre
$10 are included in the Table S3). The frequencies and
proportions of samples with antibody titre $40 in the age groups
are displayed in Table 1. In the age group 18–29 years there was
no significant difference in proportions of pre-pandemic cross-
reactive antibodies at titre $40 in samples collected in Nov 2008–
Feb 2009 and in samples collected in Mar–Apr 2009 (p=0.88), the
proportion were 12.2% (95% CI 6.3–19.8) and 11.6% (95% CI
3.9–25.1), respectively.
Post-pandemic samples
The measured antibody titres in the post-pandemic sample
ranged from 10 to 1280. The overall GMT in the group was 10.6
(95% CI 8.6–12.8). The age groups 18–29, 30–39, and 40–49 had
a significant increase in GMT with the highest increase in the
group aged 18–29. GMT by age group in the samples from the
Figure 1. GMT by age group in pre-pandemic and post-
pandemic period. In the six age groups in the pre-pandemic sample
the GMT ranged from 5.8 to 7.9. GMT in those aged 18 to 29 years (7.9)
in comparison to those 30 years of age and older (5.9) was significantly
higher. When comparing pre- and post-pandemic results, age groups
18–29, 30–39 and 40–49 had significant increase in GMT with highest
increase in the age group 18–29 years.
doi:10.1371/journal.pone.0021340.g001
Table 1. Number and proportion of observations with reactive antibody titre $40 by age groups in pre- and post-pandemic
samples and difference in proportions between pre- and post-pandemic samples.
Pre-pandemic Post-pandemic Difference
Age groups (years) N/Total % (95%CI) N/Total %, (95%CI) %, (95%CI)
18–29 16/128 12.5 (7.3–19.5) 28/66 42.4 (30.3–55.2) 29.9 (16.7–43.2)
30–39 3/98 3.1 (0.6–8.7) 11/51 21.6 (11.3–35.3) 18.5 (6.7–30.3)
40–49 3/132 2.3 (0.5–6.5) 14/68 20.6 (11.7–32.1) 18.3 (8.4–28.3)
50–59 7/167 4.2 (1.7–8.4) 6/59 10.2 (3.8–20.8) 6.0 (22.3–14.3)
60–69 7/199 3.5 (1.4–7.1) 2/48 4.2 (0.5–14.3) 0.6 (25.6–6.9)
$70 3/121 2.5 (0.5–7.1) 2/42 4.8 (0.6–16.2) 2.3 (24.7–9.3)
doi:10.1371/journal.pone.0021340.t001
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Table S2.
Again, those aged 18–29 had highest proportions of antibodies
as well as the highest infection rates corresponding to observed
differences between pre- and post-pandemic titres (Table 1).
Pre- and post-pandemic comparison in 3 birth cohorts
The birth cohort born after 1976 had the highest proportion of
antibodies at titre $40 in pre- and post-pandemic groups, as well
as the highest increase in seroprevalence, 29.4 (95% CI 17.4–
41.5%). Calculations for proportions of antibodies at titre $40 and
GMT by three birth cohorts are displayed in Table S4 and S5,
respectively. This result is supported by a reverse cumulative
distribution curve shown in Figure 2, which indicates a rapid
decline at higher titres in the birth cohort before 1957.
Tobit regression model
The Tobit regression model contained 1164 observations, of
which 953 observations were left-censored. The final model
obtained from the model selection procedure contained age,
sampling period, and vaccination status as main effects together
with an interaction between the age group and the sampling
period (the likelihood ratio test for the interaction term was
p=0.005). We estimated that the GMT of the uncensored titre
between pre- and post-pandemic period increased by a factor of
10.2 in the birth cohort born after 1976, 6.3 for those born
between 1957 and 1976, and as well as 2.4 in those born before
1957. Furthermore, those vaccinated at least once in their lifetime
against seasonal influenza had an overall higher titre compared to
those not vaccinated, i.e. by factor of 1.9. No interaction between
the vaccination and sampling period or age existed, i.e. the
increase is the same in pre- and post-pandemic samples. Results of
the Tobit regression are summarized in Table 2.
Discussion
By analysing samples from a representative nationwide health
survey collected in the year preceding the start of the pandemic,
we show that the level of pre-existing antibodies at titre $40 cross-
reacting with the pandemic influenza (H1N1) 2009 virus ranged
between 2.3, and 12.5%, depending on age group. The highest
proportions of cross-reactive antibodies before the pandemic were
observed among 18–29 year olds.
Our findings of higher titres of cross-reactive antibodies among
young adults is in contrast to other studies showing higher levels of
pre-pandemic cross-reactive antibodies among elderly [9,12–18].
However, published findings vary markedly among different
Figure 2. Reverse cumulative distribution curves by birth
cohort. Reverse cumulative distribution curves for pre-pandemic and
post-pandemic samples by birth cohorts A) after 1976 (18–32 years), B)
between 1957 and 1976 (33–52 years), C) before 1957 ($53 years) and
measured antibody titres.
doi:10.1371/journal.pone.0021340.g002
Table 2. Investigated effects of age group, sampling period
and vaccination on titre using the final Tobit regression
model.
Increase in titre: Factor 95% CI
between pre- and post-pandemic period
in age group 18-32
10.2 5.0–20.7
between pre- and post-pandemic period
in age group 33–52
6.2 3.3–11.9
between pre- and post-pandemic period
in age group $53
2.4 1.3–4.3
if vaccinated with seasonal vaccine 1.9 1.3–2.7
The table shows increase in uncensored titre
doi:10.1371/journal.pone.0021340.t002
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more prevalent in those older than 60 years of age [13], while in
Finland only those 80 years and older had high level of pre-
existing cross reactive antibodies [9]. As only a few serum samples
from individuals older than 80 years (oldest participant 86 years)
were included among the pre-pandemic sample in our study, we
cannot exclude, that individuals who were born in the years after
1918 have higher pre-existing cross-reactive antibodies. The
presence of cross-reactive antibodies in other age groups varies
also between different studies. In Italy, UK, and Australia there is
some level of pre-existing cross-reactive antibodies found among
all age groups with a common trend of higher proportions among
older individuals [14,15,26], while in Finland, Norway, and US
there was only little evidence of cross-reactive antibodies in other
age groups than elderly [9,13,27]. In Hong Kong only minor levels
of pre-pandemic cross-reactive antibodies in the population with
no age-specific trend is reported [28].
These differences might be related to the methodological
differences in the type and period of sample collection. We
analysed samples collected over a 6 month-period directly prior to
the start of the pandemic in Germany; in Italy samples from 2003–
2004 [15] and in Finland samples from 2004–2005 were analysed
[9]. Our analysis stratified by three and six age groups,
respectively, suggest that also recently circulating H1N1 strains
and vaccination history might have influenced the level of cross-
reactive antibodies in German adult population. The last season
when seasonal H1N1 influenza viruses dominated in Germany
and Europe was 2000/2001 and co-dominated in 2007/2008
[29,30]. Variation in the epidemiology of circulating subtypes
between countries might also explain the different findings in the
seroprevalence studies [31–33]. This has to be taken into account
when comparing serological results.
The sources of sera also differ among the studies. Hancock et al.
in the US used 660 stored samples from blood donors and
vaccination studies and 417 collected human sera [13]. In the UK,
1403 samples from the patients accessing health care were
analysed [14] and in Italy 587 samples were obtained from a
seroepidemiological study [15]. In Finland, 1031 stored samples
from hospital virology laboratory [9], in Hong Kong sera blood
donors, hospital outpatients and community study [28] and in
Norway age- and geographically representative residual sera from
hospital laboratories were analysed [27]. Using samples collected
for other purposes might lead to selection bias with overrepresen-
tation of healthy young adults (e.g. vaccination studies) or persons
with particular health problems (e.g. patients accessing health care,
hospital laboratory, and vaccination studies). These groups might
have different exposure to pH1N1 than general population as well
as differences in immunological response. In our study we used a
subsample from a population based representative nation wide
survey.
Another explanation for the variable results might be related to
the differences in laboratory procedures; in our study – as well as
the study in Finland, Norway and Australia – HI titres were
determined [9,26,27], while some of the other studies used
microneutralisation assays (MN) [12,13,16,28] or both [14,34].
Due to the problems of reproducibility of the HI as well as MN
methods between laboratories the levels of detected antibody titres
may differ among studies if methods are not standardized [35,36].
Our comparison of reactive antibody prevalence against
pH1N1 in pre- and post-pandemic sera indicates that in Germany
around one third of those aged 18–29 years and around one fifth
of those 30–49 years of age were infected with 2009 pandemic
influenza A (H1N1). While those 50 years of age and older had no
detectable increase in the proportions of reactive antibodies at titre
$40. However, analysing individual titres using Tobit modelling
(i.e. analysing continuous titre as opposite to dichotomized value)
with three birth cohorts adjusting for vaccination, we showed that
those born before 1957 had a significant increase in the GMT, but
that the increase was the smallest in the three birth cohorts. A
similar study from Canada observed the lowest rate of titre $40 in
those 50–79 years old after the pandemic [34]. A study by Miller
et al. found no measurable difference between pre- and post-
pandemic period in England among those 45 years and older [14].
A study by Bandaranayake et al. describes higher infection rates in
younger individuals and almost no measurable infection rates
among elderly [18].
In the literature the presence of cross-reactive antibodies among
the elderly as well as lower infection rates during the pandemic are
explained by cross-reactive immunity due to previously circulating
influenza A (H1N1) strains. The correlation between the HI and
clinical protection has been documented for seasonal influenza
viruses and HI titre in the range of 30–40 is generally accepted to
be associated with a 50% reduction in the risk of influenza
infection or disease in a population [37]. In our study, those over
50 years of age had lower proportions of pre-existing cross-reactive
antibodies and at the same time lower infection rates. One of the
possible reasons for lower risk of infection among older individuals
could be pre-existing immunity not detectable by cross-reactive
antibodies. This is supported by our results showing that those
younger than 50 years of age had highest levels of cross-reactive
antibodies prior pandemic as well as highest infection rates. This is
in concordance with higher notification rates in those adults
younger than 50 in comparison to those over 50 years of age [8].
Other possible explanations are that the older age groups were
possibly less affected by pH1N1 infection as they had less contact
with younger age groups, or that due to weaker immune response
we observe lower reactive antibody levels among elderly.
Moreover, infection and vaccination can induce T-cell mediated
immune response in humans and it has been shown that some
memory T-cell immunity against (H1N1) 2009 is present in the
adult population [38–40].
Our study has some key characteristics that the aforementioned
studies lack. We analysed a representative sample set that was
collected 6 months before the pandemic for the pre-pandemic
analysis and right after the pandemic for the post-pandemic
analysis. Due to the availability of vaccination cards, we were able
to control for the effect of pandemic vaccination on measured
antibody titres in the post-pandemic period. Moreover, our study
is population-based, while other studies used samples from specific
groups, e.g. blood donors (healthy donor effect) or hospitalised
persons [9,13–15,27,28]. We believe that these characteristics are
the major strengths of our investigation.
Limitations
Potential bias introduced by our analysis is that for the pre-
pandemic period we used vaccination information based on
either recall or vaccination card, but for the post-pandemic
period only vaccination cards were used. For those with the
vaccination cards the proportion of vaccinated is considerably
lower than for those based on recall. We expect this to be due to
the influenza vaccination not always being recorded on the
vaccination card. Thus for the post-pandemic sample we might
underestimate the amount of vaccination. To quantify possible
bias we re-fitted the models using only those with vaccination
cards for the pre-pandemic sample. We found that the general
magnitude and direction of effects was the same as in model with
the complete pre-pandemic sample. Significance of all covariates
was slightly reduced with vaccination being the only variable not
Cross-Reactive Antibodies to 2009 Pandemic H1N1
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21340significant anymore. Thus, our strategy provided greater power
for the analysis without introducing serious bias. With respect to
the regional representativeness: 3 and 7 (of the 16) federal states
are not represented in the pre-pandemic and post-pandemic
samples, respectively. Still, our results are valid on the German
population level, since the smaller federal states are the ones
missing and it is fair to assume an equal geographic impact of the
pandemic.
As the DEGS study recruited only adults we have no data on
the children population. Note also that the DEGS survey is in
principle a stratified cluster sample and the clustering was not
taken into account in parts of the analysis. Consequently, some of
the reported CIs and p-values might be too optimistic, i.e.
understating the actual uncertainty. However, since the DEGS
study is still ongoing and thus no survey weights are immediately
available, the average cluster size is only 25.6 individuals and our
subset of post-pandemic vaccination card holders is a greater
concern in terms of representativeness than sampling design. We
applied additional survey sample methodology for the estimation
only of overall proportions and overall GMT.
Conclusion
We conclude that the infection rates differed among age groups
and that the measured pre-pandemic level of cross-reactive
antibodies towards pH1N1 did not add information in relation
to protection and prediction of the most affected age groups
among adults in the pandemic. Further immunological studies and
development of better correlates of protection are needed. This
would enable more reliable targeting of preventive measures such
as vaccination, and would therefore be an important step in
preperation for the next pandemic.
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